



## €20 million pool financing from Cassa Centrale and Banca Monte Pruno to support the growth of Genetic S.p.A.

**Trento, 12 November 2025** - As part of its strong ties with local businesses and with the coordination of the **Parent Company Cassa Centrale Banca**, an important financing transaction has been completed in favour of **GENETIC S.p.A.**, a company leading in the pharmaceutical sector, specialising in the research, development, production and marketing of innovative therapeutic solutions.

The pool loan promoted by **Banca Monte Pruno**, with the intervention of **Cassa Centrale Banca as Arranger and Lead Bank**, is aimed at encouraging the research and development activities of **GENETIC S.p.A.** The total investment amounted to **€20 million** and is intended to support the company's working capital and business development.

**GENETIC S.p.A.** is an integrated pharmaceutical company - authorised by AIFA (Italian Medicines Agency) - specialised in the research, development and production of respiratory and ophthalmic products (corticosteroids, eye drops, nasal sprays, etc.). Always managed by the Pavese family, the company operates both on its own account and as a CDMO (Contract Development Manufacturing Organisation), now reaching over 40 international markets and serving 5 million patients worldwide.

Established in 2000 by **Mr. Rocco Carmelo Pavese**, current CEO, Genetic is headquartered in Castel San Giorgio (SA) and has its operational centre in Fisciano (SA). It is an Italian company boasting a high level of innovation in its processes and business activities.

"We have succeeded – stated **the General Manager of Banca Monte Pruno, Cono Federico** – in carrying out a development operation that confirms our local commitment to leading companies in our territory, thanks to the fundamental support of the Parent Company's Credit Department. In addition to its corporate value, GENETIC S.p.A. is a source of pride for the whole of southern Italy, thanks to its entrepreneurial spirit and ability to play a leading role on the international stage".

"We are proud - declared the **CEO of GENETIC S.p.A., Rocco Carmelo Pavese** - to have concluded an important financing transaction with Cassa Centrale and BCC Monte Pruno. The funding will help us strengthen our ability to develop new drugs and our R&D department by increasing the recruitment of new researchers.

This demonstrates that the synergies of the Cassa Centrale Group, in collaboration with Banca Monte Pruno, can yield excellent operating results and compete with large financial groups".

"We are very pleased – commented **the Head of Corporate and Structured Finance of Cassa Centrale Banca, Stefano Nicolini** – to have completed this important transaction, which supports the development projects of companies operating in a strategic area for our Group, namely the



Province of Salerno. We will continue to make our Group's financial resources available with the aim of promoting economic growth in the communities we serve, fostering the consolidation of the employment fabric and increasing local GDP in full accordance with the mutualistic purpose of our Cooperative Banking Group".

By carrying out transactions of this type throughout the country, the **Cassa Centrale Group**, together with its affiliated banks, is intensifying its efforts to promote entrepreneurial excellence and growth, together with related industries, by diversifying its activities in various economic sectors, as in this case, in the pharmaceutical sector.

*The **Cassa Centrale – Credito Cooperativo Italiano Group** comprises 65 BCCs (cooperative credit banks), rural banks and Raiffeisenkassen, with 1,498 branches throughout Italy, more than 12,000 employees and over 490,000 cooperative members. With total assets of €91 billion as at 30 June 2025, the Group ranks among Italy's top ten.*